Director-affiliated fund sells $127.4M in Cogent Biosciences stock
COGT has more than doubled off its 52-week low of $3.72.
Summary
A director-affiliated fund, Fairmount Funds Management LLC, sold $127.4 million worth of Cogent Biosciences stock in a significant open market transaction.
Key Events · Ownership and Investor Activity · COGT
-
Significant Insider Sale
Fairmount Funds Management LLC, an entity affiliated with a director, sold 3,500,000 shares of Cogent Biosciences common stock for a total value of $127,400,000.
-
Substantial Stake Reduction
The sale represents a significant portion of the company's market capitalization and reduces the reporting owner's common stock holdings to 5,503,418 shares post-transaction.
-
Transaction Details
The shares were sold at a price of $36.40 per share on January 22, 2026, which is below the current stock price of $39.53.
Analysis · COGT · Life Sciences
Fairmount Funds Management LLC, an entity affiliated with a director, executed a substantial open market sale of Cogent Biosciences stock totaling $127.4 million. This significant disposition, representing over 2% of the company's market capitalization, could signal a reduction in conviction from a key institutional investor and director-affiliated entity. The shares were sold at $36.40, below the current market price of $39.53. Investors should monitor for further insider activity or any related company announcements.
At the time of this filing, COGT was trading at $39.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6B. The 52-week trading range was $3.72 to $43.73. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.